Mechanism
Reduces appetite and improves glucose handling — the same biology behind human GLP-1 weight-loss drugs.
TechnicalGLP-1 receptor agonism slows gastric emptying, increases satiety via hypothalamic pathways, enhances glucose-dependent insulin secretion.
Reported uses by species
| Species | Indication | Tier | Honest evidence note |
|---|---|---|---|
| Cats | Overweight/obesity | In clinical trials | MEOW-1 (VCT25005930): randomized, placebo-controlled trial of ultra-long-acting OKV-119 implant in ~50 client-owned cats; first cat dosed Dec 2025. |
| Dogs | Metabolic/weight management | Investigational | Active research area; no approved indication yet. |
Suggested starting protocol
Starting points only — clinical judgment required. Dosing unlocks for verified veterinary accounts.
Professional-use acknowledgment
Confirm you are a veterinary professional
Dosing tables on monographs are for licensed veterinary professionals using independent clinical judgment.
- • I am a licensed veterinary professional accessing this content for clinical use.
- • I will exercise independent clinical judgment for every patient.
- • I understand evidence labels reflect the current state of published research.
Monitoring, contraindications & do-not-use-if
Pre-existing pancreatitis history. Not for diabetic cats outside trial protocol. FDA filing targeted 2027–2028.
The evidence
- OKAVA press release (Dec 2025) — first cat dosed in MEOW-1OKAVA Pharmaceuticals
- VeterinaryClinicalTrials.org listing VCT25005930VeterinaryClinicalTrials.org